Genomictree

Genomictree Interest Coverage

The Interest Coverage Ratio of Genomictree (228760.KQ) as of Nov 3, 2026 is -3.17. In the previous year, Interest Coverage Ratio was -4.18 — a change of -24.23% (higher).

Interest Coverage

-3.17

YoY

-24.23%

Last updated:

Interest Coverage Ratio of Genomictree is 2024 -3.17 . Interest Coverage Ratio of Genomictree was 2023 -4.18 . It decreases by -24.23% higher compared to the previous year.

The Genomictree Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2016
-0.51 KRW
Jan 1, 2017
-202.67 KRW
Jan 1, 2019
-2.22 KRW
Jan 1, 2020
-20.87 KRW
Jan 1, 2021
-5.48 KRW
Jan 1, 2022
0.51 KRW
Jan 1, 2023
-4.18 KRW
Jan 1, 2024
-3.17 KRW
The Genomictree Interest Coverage history
YEARInterest CoverageYoY
-3.17-24.23%
-4.18-918.97%
0.51-109.31%
-5.48-73.72%
-20.87+838.19%
-2.22-98.90%
-202.67+39,386.11%
-0.51-64.52%
-1.45—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomictree Stock analysis

What does Genomictree do? Genomictree, Inc. generates revenue by developing and supplying diagnostic products focused on cancer screening and prognosis. The firm conducts genomic analysis using microarrays and next generation sequencing analysis, while also performing clinical trials for its molecular diagnostic products. These offerings are designed to support medical professionals in identifying and managing various oncological conditions through advanced genetic testing methodologies. The company’s product portfolio is divided into cancer molecular diagnostic products and molecular genetic diagnostic products. The cancer molecular diagnostic segment includes specific tests for colorectal cancer, bladder cancer, lung cancer, stomach cancer, and cervical cancer. This targeted approach allows the firm to address a broad spectrum of oncological needs within the diagnostic market. Within the molecular genetic diagnostic products category, Genomictree, Inc. provides epidermal growth factor receptor (EGFR) mutation diagnosis and human papilloma virus (HPV) diagnostic products. By offering these specialized genetic tests, the company serves the healthcare sector with tools necessary for precise patient diagnosis and treatment planning based on genomic data. Genomictree is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomictree stock

Interest Coverage Ratio of Genomictree is -3.17 in 2024.

Interest Coverage Ratio of Genomictree changed from -4.18 to -3.17, representing a -24.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Genomictree since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Genomictree with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Genomictree

All Key Metrics — Genomictree